It is to be noted that small molecule inhibitors of TNF/TNFR proteins may still suffer from some of the same limitations plaguing biologic therapeutics, i.e., low responder rates, and opportunistic infection and malignancy risks. Here, TNF is linked to Opportunistic infection.